Live Kinase B1 Maintains CD34CD38 AML Cell Proliferation and Self-renewal

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2017 Apr 12

PMID 28397012

Citations 1

Authors

Huihan Wang

Xiaobin Wang

Na Xin

Lin Qi

Aijun Liao

Wei Yang

Zhuogang Liu

Chenghai Zhao

Affiliations

Soon will be listed here.

Abstract

Live kinase B1 (LKB1) has been recognized as a tumor suppressor in many human cancers; however, LKB1 maintains self-renewal of hematopoietic stem cells (HSCs). The existence of leukemia stem cells (LSCs) is responsible for drug resistance and leukemia relapse. In acute myeloid leukemia (AML), CD34CD38 fraction is the most enriched compartment for LSCs. We found that LKB1 was upregulated in CD34CD38 AML cells. LKB1 downregulation suppressed the long-term proliferation of CD34CD38 AML cells, induced CD34CD38 AML cells into G2/M phase, and enhanced the sensitivity of CD34CD38 AML cells to chemotherapy. Furthermore, LKB1 downregulation in CD34CD38 AML cells inhibited tumor formation in NOD-SCID mice. Downregulation of LKB1 gene makes LSCs partly loose the characters as stem cells. Gene expression microarray showed that MAPK/ERK pathway was implicated in the regulation of CD34CD38 AML cell proliferation by LKB1. Together, these findings demonstrate that LKB1 plays an important role in the maintenance of LSCs, which may be responsible for drug resistance and AML relapse.

Citing Articles

Family Aggregation of Hematological Malignancies Discovered from an Acute Myeloid Leukemia Patient with STK11 and THBD Gene Mutation.

Zhang N, Miao X, Shuai Y, Yao H, Fan F, Liu Y Case Rep Oncol. 2023; 16(1):734-738.

PMID: 37900785 PMC: 10601766. DOI: 10.1159/000532003.

References

Gurumurthy S, Xie S, Alagesan B, Kim J, Yusuf R, Saez B . The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature. 2010; 468(7324):659-63. PMC: 3037591. DOI: 10.1038/nature09572. View

Li B, Fu J, Chen P, Ge X, Li Y, Kuiatse I . The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. J Biol Chem. 2015; 290(50):29854-68. PMC: 4705994. DOI: 10.1074/jbc.M115.664953. View

Marignani P . LKB1, the multitasking tumour suppressor kinase. J Clin Pathol. 2004; 58(1):15-9. PMC: 1770539. DOI: 10.1136/jcp.2003.015255. View

Grahame Hardie D . AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8(10):774-85. DOI: 10.1038/nrm2249. View

Nakada D, Saunders T, Morrison S . Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature. 2010; 468(7324):653-8. PMC: 3059717. DOI: 10.1038/nature09571. View

Chavez-Gonzalez A, Bakhshinejad B, Pakravan K, Guzman M, Babashah S . Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cell Oncol (Dordr). 2016; 40(1):1-20. PMC: 5842429. DOI: 10.1007/s13402-016-0297-1. View

Shaw R, Bardeesy N, Manning B, Lopez L, Kosmatka M, DePinho R . The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004; 6(1):91-9. DOI: 10.1016/j.ccr.2004.06.007. View

Reinisch A, Chan S, Thomas D, Majeti R . Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin Hematol. 2015; 52(3):150-64. PMC: 5516648. DOI: 10.1053/j.seminhematol.2015.03.008. View

Sanchez-Cespedes M . A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007; 26(57):7825-32. DOI: 10.1038/sj.onc.1210594. View

10.

Pelosi E, Castelli G, Testa U . Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015; 55(4):336-46. DOI: 10.1016/j.bcmd.2015.07.015. View

11.

van Lier M, Wagner A, Mathus-Vliegen E, Kuipers E, Steyerberg E, van Leerdam M . High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010; 105(6):1258-64. DOI: 10.1038/ajg.2009.725. View

12.

Schepers K, Campbell T, Passegue E . Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015; 16(3):254-67. PMC: 4391962. DOI: 10.1016/j.stem.2015.02.014. View

13.

Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa J . Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood. 2009; 114(8):1498-505. DOI: 10.1182/blood-2009-03-209734. View

14.

Hezel A, Bardeesy N . LKB1; linking cell structure and tumor suppression. Oncogene. 2008; 27(55):6908-19. DOI: 10.1038/onc.2008.342. View

15.

Kikushige Y, Miyamoto T . Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia. Oncology. 2015; 89 Suppl 1:28-32. DOI: 10.1159/000431062. View

16.

Hu Y, Li S . Survival regulation of leukemia stem cells. Cell Mol Life Sci. 2015; 73(5):1039-50. PMC: 11108378. DOI: 10.1007/s00018-015-2108-7. View

17.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

18.

OBrien J, Rizzieri D . Leukemic stem cells: a review. Cancer Invest. 2013; 31(4):215-20. DOI: 10.3109/07357907.2012.700986. View

19.

Zhang P, Yang Y, Fu C, Xiang L, Wang Q, Li X . Pathways involved in the evolution of leukemic stem cells. Eur Rev Med Pharmacol Sci. 2015; 19(8):1356-63. View

20.

Sarry J, Murphy K, Perry R, Sanchez P, Secreto A, Keefer C . Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 2010; 121(1):384-95. PMC: 3007135. DOI: 10.1172/JCI41495. View